| LESTR | leukocyte-derived seven-transmembrane domain receptor |
|---|---|
| VH | variable domain of heavy chain; variable heavy chain |
| VL | variable domain of the light chain; variable light chain |
| CLIP | Corticotropin-Like Intermediate Peptide |
| IGF | Insulin-like Growth Factor = Somatomedin |
| Csk-like protein-tyrosine kinase | <enzyme> Phosphorylates c-terminal conserved tyr of src family members; from mouse brain; has 52% identity with mouse csk; mw 52 kD; genbank u05210 Registry number: EC 2.7.1.- Synonym: ctk (kinase), ctk gene product, csk-type protein-tyrosine kinase, ntk (kinase), bhk (kinase) (26 Jun 1999) |
|---|---|
| cyanobacterium-like bodies | A Cryptosporidium-like genus of coccidian parasites reported from millipedes, reptiles, insectivores, and a rodent species. Cyclospora is characterised by acid-fast oocysts with two sporocysts, each with two sporozoites. Cyclospora species is an undescribed but distinct species of Cyclospora that is implicated as the cause of a widespread, prolonged but self-limited human diarrhoea in patients in North, Central, and South America; Caribbean countries; Southeast Asia; and eastern Europe previously reported as caused by cyanobacterium-like bodies. Synonym: cyanobacterium-like bodies. (05 Mar 2000) |
| hepatitis c-like viruses | A genus of flaviviridae causing parenterally-transmitted non-a, non-b hepatitis (hepatitis c) which is associated with transfusions and drug abuse. Hepatitis c virus is the type species. (12 Dec 1998) |
| Shiga like toxin | <protein> Group of structurally related toxins that block eukaryotic protein synthesis by cleaving the 28S rRNA subunit of ribosomes. Examples: Shiga toxin, Shiga like toxins SLT 1 and SLT 2 of Escherichia coli. (18 Nov 1997) |
| SLE-like syndrome | <syndrome> A disease with manifestations suggestive of systemic lupus erythematosus, without meeting diagnostic criteria for that disease; sometimes used for drug-induced lupus. (05 Mar 2000) |
| neoplastic endocrine-like syndromes | Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm. (12 Dec 1998) |
| nonsuppressible insulin-like activity | A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity. (12 Dec 1998) |
| insulin-like activity | A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin. (05 Mar 2000) |
| insulin like growth factor | <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin. They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present). Insulin like growth factor I = somatomedin A = somatomedin C Insulin like growth factor II = MSA (Multiplication stimulating activity). Insulin like growth factor 1 is released from the liver in response to growth hormone. Acronym: IGF (18 Nov 1997) |
| insulin-like growth-factor binding protein 1 | One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29) (12 Dec 1998) |
| insulin-like growth factor-binding protein 2 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth factor binding protein 3 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin like growth-factor-binding protein 4 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like growth-factor-binding-protein 5 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |
| insulin-like-growth-factor-binding protein 6 | One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level. (12 Dec 1998) |